Sign up for Table of Contents Alerts.
Email this page
Print this page
Commentary
Topotecan in Small Cell Lung Cancer: First or Second Line?
Barbara G. Campling
volume 3 | issue 1
jan 2004Pages: 094-095
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Commentary to:
A Phase II Study of Topotecan and Cyclophosphamide with G-CSF in Patients with Small Cell Lung Cancer with Poor Prognostic Factors
Erole M. Hobdy, Eric Kraut, Gregory Masters, Kathleen Blum, Anne McKeon,Boyd Byrd and John R. Murren
Correspondence to: University of Pennsylvania, and the Philadelphia VA Medical Center; University and Woodland Avenues, Philadelphia, PA, 19104, USA; Email: camplinb@mail.med.upenn.edu
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.